Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso.
for the STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Lancet, 359 (2002), pp. 2072-2077
[2.]
J.L. Chiasson, R. Gomis, M. Hanefeld, R.G. Josse, A. Karasik, M. Laakso.
for the STOP-NIDDM Trial Research Group. An international study on the efficacy of an alfa-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design and preliminary screening data.
Diabetes Care, 21 (1998), pp. 1720-1725
[3.]
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso.
for the STOP-NIDDM Trial Research Group. Acarbose can prevent type 2 diabetes and cardiovascular disease in subjects with impaired glucose tolerance: the STOP-NIDDM Trial.
Diabetologia, 45 (2002), pp. A104
[4.]
J. Tuomilehto, J. Lindstrom, J.G. Eriksson, T.T. Valle, H. Hamalainen, P. Ilanne-Parikka, et al.
for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.
N Engl J Med, 344 (2001), pp. 1343-1350
[5.]
W.C. Knowler, E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker, et al.
for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
N Engl J Med, 346 (2002), pp. 393-403
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición